Literature DB >> 1650324

Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study.

F Z al-Faleh1, E A Ayoola, M al-Jeffry, R al-Rashed, M al-Mofarreh, M Arif, S Ramia, M al-Karawi, M al-Shabrawy.   

Abstract

In a population-based survey, 39 (0.90%) of 4,496 Saudi Arabian children (ages 1 to 10) were positive for antibody to hepatitis C virus. No significant difference was seen between the prevalence rate in males (0.9%) and females (0.8%) or between urban (0.7%) and rural dwellers (1.0%). A significant variation of rates (0% to 5.7%) was seen from one region to another. The Gizan population, noted for hyperendemic hepatitis B virus infection, had the highest prevalence of antibody to hepatitis C virus despite its cultural and socioeconomic similarities to other regions. In some regions of Saudi Arabia the prevalence of antibody to hepatitis C virus among children was 0% despite endemic rates for both hepatitis B virus and hepatitis A virus infections. An inverse relationship between age and antibody to hepatitis C virus positivity was noted, suggesting an early acquisition of infection in the population studied. Although the overall prevalence of antibody to hepatitis C virus in Saudi children appears low, endemic foci exist where transmission of infection appears to occur early in childhood. The significance of this characteristic for the incidence of chronic sequelae of hepatitis C virus infection needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650324

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

Review 1.  Hepatitis C in childhood.

Authors:  F Bortolotti
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

2.  Prevalence of hepatitis A, B, and C markers in school children of a rural area of Crete, Greece.

Authors:  C Lionis; E Frangoulis; M Koulentakis; E Biziagos; E Kouroumalis
Journal:  Eur J Epidemiol       Date:  1997-06       Impact factor: 8.082

Review 3.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 4.  Chronic viral hepatitis.

Authors:  M H Chang
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

5.  Low prevalence of anti-HCV antibody among Italian children.

Authors:  L Romanò; A Azara; M Chiaramonte; D De Mattia; A Giammanco; M E Moschen; B Scarpa; T Stroffolini; A R Zanetti
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

Review 6.  Viral hepatitis.

Authors:  G V Gregorio; G Mieli-Vergani; A P Mowat
Journal:  Arch Dis Child       Date:  1994-04       Impact factor: 3.791

Review 7.  Potential for human immunodeficiency virus parenteral transmission in the Middle East and North Africa: an analysis using hepatitis C virus as a proxy biomarker.

Authors:  Yousra A Mohamoud; F DeWolfe Miller; Laith J Abu-Raddad
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

8.  Chronic non-A, non-B hepatitis: role of hepatitis C virus.

Authors:  R Iorio; S Guida; S Porzio; I Fariello; A Vegnente
Journal:  Arch Dis Child       Date:  1993-02       Impact factor: 3.791

9.  The prevalence of hepatitis C virus (HCV) in infants and children after liver transplantation.

Authors:  M J Nowicki; N Ahmad; J E Heubi; I K Kuramoto; B M Baroudy; W F Balistreri
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

10.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Authors:  Hamad Al Ashgar; Ahmed Helmy; Mohamed Q Khan; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Abdullah Alshehri; Abdullah Al Kalbani; Khalid Al Swat; Salim Dahab; Naser Elkum; Mohammed Al Fadda
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.